Theranos promised a blood test that required a fingerstick rather than a venous draw, run on a compact device that could sit in a pharmacy, delivering results for hundreds of assays from a few drops. If it had worked it would have been an enormous public good, and Elizabeth Holmes described it in exactly those terms: a world in which nobody has to say goodbye too soon.
It did not work. The proprietary device could run a small number of tests unreliably. The great majority of the tests Theranos offered commercially were run on modified conventional analyzers made by other companies, using diluted samples that degraded accuracy. In 2016 the company voided or corrected two years of results from its Edison devices — tests that had been used by real patients to make real medical decisions.
The mechanism that kept the company at a nine-billion-dollar valuation for years is the one that recurs in this part of the guide, and Theranos ran it in its most concentrated form.
Its board included Henry Kissinger, George Shultz, William Perry, Sam Nunn, James Mattis and two former senators. Almost none of them had any background in laboratory medicine or diagnostics. What they supplied was not oversight but credibility — a transplant of institutional authority from one domain to another, and an implicit assurance to investors that people of this stature would not lend their names to something they had not checked. They had not checked. They were not in a position to.
The investors were, mostly, not the biotech specialists who would have demanded the peer-reviewed validation data and would not have been given it. They were family offices, private investors and venture funds without diagnostics expertise, buying into a founder narrative.
And the narrative carried a moral charge, which is the second mechanism. Paul Slovic's work on the affect heuristic finds that strong positive feeling about an outcome systematically lowers the perceived risk of the means. A company promising to end unnecessary death by needle is harder to interrogate than a company promising a better assay margin, because interrogation feels like an argument against the goal.
Secrecy did the rest. Employees were siloed and bound by aggressive NDAs, litigation was used against departing staff, and demonstrations for visitors were staged — a device would be shown running, the sample would be processed elsewhere. What outsiders were permitted to evaluate was a performance, and the performance became the object of belief in place of any data.
It ended through people. Tyler Shultz, a young employee and the grandson of the board member, raised concerns internally, was pressured, and went to the regulator. Erika Cheung filed a complaint with CMS. John Carreyrou published in the Wall Street Journal in October 2015.
Holmes was convicted in January 2022 on four counts of defrauding investors, and sentenced to 135 months.
Note what the jury did not convict on: the counts relating to defrauding patients did not produce convictions. The investors were found to have been defrauded; the people whose blood was tested were, legally, a harder case.